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Abstract
Background and aims: Patients with HIV and hepatitis C virus (HCV) coinfection are at
increased risk of developing hepatic steatosis. The aims of this study were to assess the prevalence
of steatosis in a cohort with HIV-HCV coinfection, and to determine an association, if any, between
steatosis, antiretroviral therapy (ART), and advanced hepatic fibrosis.
Patients and methods: HIV-HCV coinfected patients were retrospectively identified from the
HIV clinic. ART was classified as none, nucleoside reverse transcriptase inhibitors (NRTIs) only,
highly active antiretroviral therapy (HAART) only, and sequential therapy (initial NRTIs followed
by HAART). Fibrosis stage and necroinflammation grade were assessed by the modified HAI (Ishak)
scoring method. Steatosis was graded as 0–3.
Results: Sixty patients were identified. The overall prevalence of hepatic steatosis was 58%. Those
that received HAART only had a lower prevalence of steatosis (41%) compared to those on NRTIs
only (70%) or sequential therapy (82%). Independent predictors of hepatic steatosis were absence
of HAART only therapy, OR 2.9, p = 0.09, and presence of cirrhosis, OR 4.6, p = 0.044. Forty five
percent of the patients had advanced fibrosis (fibrosis stage ≥ 3). NI grade (OR 1.9, p = 0.030), and
steatosis grade (OR 3.6, p = 0.045), were independent predictors of advanced fibrosis.
Conclusion: Hepatic steatosis is associated with more advanced hepatic fibrosis in the HIV-HCV
coinfected population. HAART only therapy (rather than NRTIs only or sequential therapy)
appears to be associated with a lower prevalence of hepatic steatosis. This may be one of the
mechanisms by which HAART could attenuate hepatic fibrosis in such a cohort.
Introduction
Highly active antiretroviral therapy (HAART) has signifi-
cantly improved survival in patients with human immun-
odeficiency virus (HIV) infection [1]. Increasing attention
is now being focused on co infection with other viruses
like hepatitis C (HCV). Because of similar routes of trans-
mission, approximately 25–30% of patients with HIV are
also coinfected with HCV [2]. Factors associated with
more advanced hepatic fibrosis in HCV infection include
HIV coinfection [3] and hepatic steatosis, (prevalence of
47%–79%) [4-6].
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hepatic steatosis due to multiple factors including antiret-
roviral therapy (ART), obesity, hyperglycemia, lipodystro-
phy, and coinfection with HCV [2,7-11]. In HIV-HCV
coinfection prevalence of hepatic steatosis varies between
40–72.1% [9-13]. In the coinfected population, the asso-
ciation between ART and steatosis, and whether steatosis
is associated with advanced fibrosis remains controversial
[9-11]. The aims of this study were therefore to assess
whether in those with HIV-HCV coinfection
1. Use of ART is associated with hepatic steatosis
2. Hepatic steatosis is an independent predictor of
advanced hepatic fibrosis
3. Hepatic steatosis is associated with fibrosis progression
in serial liver biopsies
Patients and methods
The study period was from 1990–2005. Patients with HIV-
HCV coinfection were identified from the Pathology and
HIV database after which, their charts and computerised
chemical pathology and histology databases reviewed. To
be included in the study the patients had to be
1. HCV antibody and or HCV PCR (qualitative) positive
2. HIV antibody positive
3. Have had a liver biopsy.
The indications for a liver biopsy in most patients were
abnormal liver tests. All the liver biopsies had been
reviewed by RG who was blinded to the clinical informa-
tion. The fibrosis stage (0–6) and necroinflammatory (NI)
grade (0–18) were assessed by the modified HAI (Ishak)
scoring system [14]. Steatosis was graded, (depending on
% of hepatocytes containing fat), into grade 0 (< 5%),
grade 1 (<33%), grade 2 (33%–66%), and grade 3
(>66%).
HCV disease duration and fibrosis progression were calcu-
lated as before [15]. Lipoatrophy was stated to be present
if mentioned in the patient records. Diabetes mellitus
(DM) was defined by presence of one or more of the fol-
lowing: fasting blood glucose > 7 mmol/l, being on anti
diabetic medications, and/or a note in the patient record
stating that there was a history of DM.
Anti-HCV antibody testing, HCV RNA and HIV RNA
quantification and HCV genotyping were performed in
the hospital virology laboratory using standard commer-
cial kits (Abbott, Bayer, Roche).
Alcohol abuse was defined as either consumption of > 3
units of alcohol/day (approximately 40 gms/day), and/or
a written note in patient records stating that there was a
history of alcohol excess. Details of ART were also
recorded to assess duration of therapy prior to the liver
biopsy. ART was classified as [16].
1. None
2. NRTIs only
3. HAART only. Those whose HIV was diagnosed in or
after 1996 and were therefore treated with HAART at
onset. For the purpose of this study HAART was defined as
use of any two nucleoside reverse transcriptase inhibitors
(NRTIs) with any protease inhibitor (PI) or non nucleo-
side reverse transcriptase inhibitors (NNRTI)
4. Sequential therapy: Those whose HIV was diagnosed
prior to 1996; hence were initially treated with NRTIs and
then converted to HAART after 1996.
Ethnicity was classified (according to the HIV database)
into White, Other European and Others.
The following patients were excluded
1. Presence of liver disease of another etiology, e.g. active
hepatitis B infection, autoimmune liver disease, genetic
hemochromatosis, and cholestatic liver disease
2. Medical records/clinical data not available
Statistical Analysis
Data are presented as mean ± SD except the HIV and HCV
viral load (VL) which are presented as median (range).
Differences between continuous variables were compared
using the Mann Whitney (U) Test and between categorical
variables by the Chi Square and Fischer's Exact Test.
Binary logistic regression analysis was performed to assess
independent predictors of hepatic steatosis and fibrosis
stage ≥ 3. The statistical software programme used was
SPSS version 14 (Chicago, IL)
Results
From 1990–2005 there were sixty-six patients with HIV
who had been coded as having had a liver biopsy for HCV.
Six were excluded, and therefore 60 patients were found
suitable for the study. Of these sixty patients 52 (87%)
had abnormal transaminases. All were HCV antibody pos-
itive, and all but one was HCV RNA (qualitative) positive.
Eight patients had undergone more than one biopsy, of
whom seven had had two and one three biopsies.Page 2 of 8
(page number not for citation purposes)
BMC Research Notes 2008, 1:46 http://www.biomedcentral.com/1756-0500/1/46Table 1 shows data in the whole cohort at the time of the
most recent biopsy. The mean age at HIV diagnosis was
33.3 ± 8.1 years. Mean duration of HIV prior to biopsy
was 6.2 ± 5.5 years. At the time of the biopsy, 53 (88%)
had a CD4 count ≥ 200 and 52% had undetectable HIV
VL. Overall, 12 had received an NNRTI, 9 a PI and 12 had
received both. As regards NRTI, 17 had received stavudine
(d4T), 13 didanosine (ddI) and 33 zidovudine (AZT). Of
the 17 who had received no ART at the time of the biopsy,
16 were long-term non-progressors.
Some degree of hepatic steatosis was present in 58% of the
patients, with the majority having grade 1 steatosis (Fig
1). Table 2 shows data in those with and without steatosis.
Those who received NRTIs only (70%) or sequential ther-
apy (82%) were more likely to have hepatic steatosis com-
pared to those that received HAART only (41%), p = 0.11
and 0.64 respectively), (Fig 2). The use of HAART only
therapy was protective against development of steatosis
(Table 2). The mean steatosis grade in the HAART only
group was 0.5 ± 0.8. This was lower than that seen in the
NRTI only (1.2 ± 1.0, p = 0.20), sequential therapy group
(0.9 ± 0.5, p = 0.63), and no therapy group (0.6 ± 0.6).
Further sub group analysis indicated the prevalence of
steatosis as follow: stavudine (70%), didanosine (61%),
zidovudine (63%), any PI therapy (62%), and any NNRTI
therapy (58%).
There was no difference in durations of different forms of
ART in those with and without steatosis (Table 2). The
overall duration of ART was longer in those with sequen-
tial therapy (94.3 ± 35.5 mths), compared to NRTI only
(22.9 ± 17.3 mths) and HAART only groups (29.9 ± 26.5
mths), p < 0.05. However presence of steatosis was not
associated with duration of ART (50.6 ± 43.0 vs. 32.7 ±
30.6 mths). Duration of stavudine (32.8 ± 21.7 vs. 45.8 ±
25.4), and didanosine (24.6 ± 16.6 vs. 31.2 ± 29.7) were
also no different in those with and without steatosis (p
value = 1.0 and 0.80 respectively). All factors that were sig-
nificantly associated with steatosis on univariate analysis
(p ≤ 0.1) (HAART only therapy, sequential therapy, and
presence of cirrhosis) were then entered into a stepwise
logistic regression model. Independent predictors of
hepatic steatosis were absence of HAART only therapy, OR
2.9 (95% CI 0.84–9.9), p = 0.09 and presence of cirrhosis,
OR 4.6 (95% CI 1.0–20.4), p = 0.044. Because of the
small sample size we could not analyze the association
between diabetes mellitus (n = 3), genotype 3 (n = 6),
lipoatrophy (n = 5) and hepatic steatosis.
Table 3 shows data in those with ≥ vs. < stage 3 fibrosis.
There were no significant differences in serum bilirubin,
transaminases and HCV VL (data not shown).
Duration of stavudine (44.9 ± 21.5 vs. 24.8 ± 20.6) and
didanosine (34.0 + 22.1 vs. 11.7 ± 10.4) were longer in
those with fibrosis stage ≥ 3, though the differences did
not achieve statistical significance (p value = 1.0 and 0.80
respectively). Factors that were significantly associated
with fibrosis stage ≥ 3 on univariate analysis (p ≤ 0.1)
(HIV diagnosed before or after 1996, cholestrol/HDL
ratio, platelet count, grade of hepatic steatosis, necroin-
flammatory grade, and CD4 counts at time of the biopsy)
were then entered into a step wise logistic regression
model. The following were independently associated with
advanced fibrosis: grade of necroinflammation (OR 1.9
Table 1: Data in whole cohort (n = 60) at the time of the most 
recent liver biopsy
Age at biopsy (yrs) 39.4 ± 8.2
Ethnicity
White 24 (40%)
Other European 24 (40%)
Others 12 (20%)
Male 54 (90%)
Weight (kg) 72.3 ± 10.1
> 75 kg 24 (40%)
Diabetes Mellitus 3 (5%)
Lipoatrophy 5 (8%)
Risk factors for HCV
IDU 32 (53%)
Blood transfusion 3 (5%)
Homosexual 19 (32%)
Heterosexual 3 (5%)
Tattoos/fisting 3 (5%)
Unknown 1 (2%)
Alcohol Abuse 18 (30%)
CD4+ (/mm3) 450 (100–1200)
HIV VL (copies/ml) UD (UD-210,955)
Antiretroviral therapy
None 17 (28%)
NRTI only 10 (17%)
HAART only 22 (37%)
Sequential therapy 11 (18%)
HCV VL (IU/ml)* 869,299 (2716–14,975,540)
HCV genotype 1* 30/42 (71%)
HCV disease duration (yrs) 16.4 ± 8.0
Liver Biopsy**
Fibrosis stage 2.8 ± 1.7
Fibrosis progression rate/yr 0.21 ± 0.16
(FPR)*
Cirrhosis 15 (25%)
Necroinflammatory grade 3.7 ± 1.7
Hepatic steatosis 35 (58%)
*HCV viral load and genotyping unavailable in 16 and 18 patients 
respectively
*FPR unavailable in 22 patients
** Data in median (range): fibrosis stage 2 (0–6), necroinflammatory 
grade 3 (1–9), fibrosis progression rate/yr 0.15 (0–0.67), steatosis 
grade 1 (0–3)
UD: undetectable
Ethnicity: In Other European the country of origin was as follows: 
Italy n = 8, Portugal n = 8, Spain n = 5, Germany n = 1, France n = 1 
and Venezuela n = 1. Others included Brazil n = 3, Russia n = 3, 
Yugoslavia n = 3, India n = 1, Iran n = 1 and Libya n = 1Page 3 of 8
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sis (OR 3.6 (95% CI 1.0–12.7), p = 0.045). There were 15
patients who had both a necroinflammatory grade ≥ 4
(mean grade in the whole group) and steatosis. Prevalence
of cirrhosis in this group was 40%, compared to 13% in
those without any of these two factors (p = 0.02). Fig 3
shows the fibrosis progression rates/year (FPR) in those
with and without hepatic steatosis. The FPR was faster in
the former though the differences did not achieve statisti-
cal significance, probably due to the small sample size.
Of the eight patients with more than one biopsy, the
mean interval between the biopsies was 52 ± 17.9
months. Five had fibrosis progression ≥ one stage of
whom 4 (80%) showed evidence of hepatic steatosis in
the index biopsy.
Discussion
This study has shown that 58% of HIV-HCV coinfected
patients (of whom 72% were on ART) have evidence of
hepatic steatosis on liver biopsy, and this is consistent
Table 2: Data in patients with and without hepatic steatosis
Hepatic steatosis Hepatic steatosis p value
Yes No
n = 35 n = 25
Age at biopsy (yrs) 39.0 ± 8.9 40.0 ± 7.2 ns
Age at HIV diagnosis (yrs) 32.9 ± 8.9 34.0 ± 6.8 ns
Male 32 (91%) 22 (88%) ns
ethnicity 14 (40%) 9 (36%) ns
Weight (kg) 74.2 ± 9.2 69.7 ± 10.8 0.74
Weight > 75 kg 17 (48%) 7 (28%) ns
Diabetes mellitus 2 (6%) 1 (4%) ns
Alcohol 11 (31%) 7 (28%) ns
Antiretroviral therapy
No therapy 10 (28%) 7 (28%) ns
NRTI 7 (20%) 3 (12%) ns
Duration (mths) 22.3 ± 18.8 21.7 ± 12.4 ns
HAART only 9 (26%) 13 (52%) 0.037
Duration (mths) 30.4 ± 27.3 29.5 ± 27.1 ns
Sequential 9 (26%) 2 (8%) 0.08
Duration (mths) 92.8 ± 37.2 106.0 ns
Received PI 13 (37%) 8 (32%) ns
Received NNRTI 14 (40%) 10 (40%) ns
Received stavudine 12 (34%) 5 (20%) ns
Received didanosine 8 (23%) 5 (20%) ns
Received zidovudine 21 (60%) 12 (48%) ns
Time from HIV diagnosis to HAART (mths) 47.4 + 38.7 40.4 + 50.9 ns
CD4 count (/mm3) 410 (110–1100) 490 (100–1200) ns
HIV VL (copies/ml) UD (UD-210955) 70 (UD-121843) ns
HCV VL (IU/ml) 441309 (2716–769231) 1286755 (29451–14975540) ns
Non 1 genotype 6/21 (28%) 6/21 (28%) ns
Cholestrol 4.3 ± 1.2 4.1 ± 1.08 ns
HDL 1.1 ± 0.5 1.1 ± 0.3 ns
Triglyceride 2.2 ± 2.0 1.5 ± 0.6 ns
Cholestrol/HDL ratio 4.8 ± 2.2 3.8 ± 1.0 ns
Fasting blood glucose 6.1 + 6.4 5.1 ± 0.9 ns
ALT (IU/L) 131 + 149.8 104 ± 74.6 ns
Fibrosis stage 3.0 ± 1.9 2.5 ± 1.7 ns
NI grade 3.7 ± 1.9 3.7 + 1.7 ns
Cirrhosis 12 (34%) 3 (12%) 0.049
Normal range for lab values: ALT <40 iu/L, Bilirubin <17 umol/L, Alkaline phosphates 30–130 iu/L, Albumin 35–41 g/L, Cholestrol <5 mmol/L, 
triglycerides <2.30 mmol/L, HDL cholesterol >1.00 mmol/L, Cholestrol/HDL <5.00 mmol/L, fasting blood glucose 3–5.5 mmol/L
HDL: high density lipoprotein
UD: undetectable
Data on lipids unavailable in 10 patientsPage 4 of 8
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either alone, or as part of sequential therapy were twice as
likely to have steatosis (70%–82%) compared to those
who had received HAART only therapy (41%). Independ-
ent predictors of hepatic steatosis were absence of HAART
only therapy, and presence of cirrhosis. Neither PI or NRTI
therapy was independently associated with steatosis. 45%
of patients had advanced fibrosis and both grade of steta-
osis and NI were independent predictors of advanced
fibrosis. In the subgroup with > 1 biopsy, 80% of those
with fibrosis progression had steatosis on the index
biopsy.
The lowest prevalence of hepatic steatosis was observed in
the HAART only group. Furthermore, the duration
between HIV diagnosis and HAART initiation was longer
for those with steatosis (47.4 vs. 40.4 months). This sug-
gests that receiving HAART early, may in some way be pro-
tective against development of subsequent hepatic
steatosis. Prior authors have also found a lower prevalence
of hepatic steatosis with certain antiretroviral drugs
(NNRTI) [1].
So how do we explain this negative association between
HAART and hepatic steatosis? It may be partly related to
the fact that NNRTIs (especially nevirapine) do not result
in insulin resistance and may also be associated with ele-
vations in high density lipoproteins (HDL) [17]. Sec-
ondly, HAART has been known to attenuate hepatic NI in
coinfected patients [16,18] and there may in fact be an
association between NI and hepatic steatosis. This could
be because the HCV core protein leads to oxidative stress
[19] and hepatic steatosis could result from the inflamma-
tion associated with this oxidative stress [20]. One could
therefore speculate that appropriately initiated HAART
could attenuate hepatic NI (either directly or via immune
restoration induced changes in inflammatory cytokines)
[21,22], which in turn may reduce hepatic steatosis.
Steatosis has been independently associated with
advanced fibrosis in HCV monoinfected patients [6,23]
though this remains controversial in HIV-HCV subjects
[9-11]. In this study, those with advanced hepatic fibrosis
had a significantly higher grade of hepatic steatosis com-
pared to those with less severe hepatic fibrosis, (consistent
with Sulkowski et al's data). In fact in our study 80% of
patients with fibrosis progression had hepatic steatosis in
the index biopsy. Also, a recent study has observed higher
prevalence of hepatic steatosis in HIV-HCV coinfected
patients compared with HCV monoinfected subjects
(72.1% vs. 52%) [14]. Therefore one of the factors con-
tributing to the accelerated fibrosis progression in HIV-
HCV coinfected patients could be the increased preva-
lence of hepatic steatosis.
The effects of HAART on liver fibrosis in HIV-HCV coin-
fected patients remain controversial. Recent data however,
do indicate that HAART may attenuate hepatic fibrosis in
this cohort especially if patients receive HAART (rather
than NRTI or sequential therapy) at onset, and if therapy
is associated with successful viral suppression [16,24].
Data from this study further corroborates this hypothesis
as 70% of those with fibrosis stage < 3 had their HIV diag-
nosed in or after 1996, indicating they were more likely to
receive HAART at onset. The underlying mechanism/s
The prevalence of hepatic steatosis (in percentage) in HIV-HCV coinf cted PatientsFigure 1
The prevalence of hepatic steatosis (in percentage) in HIV-
HCV coinfected Patients.
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Table 3: Data in patients with fibrosis stage ≥ vs. < 3
Fibrosis stage
n = 27
Age at biopsy (yrs) 40.6 ± 8.7
Age exposed to HCV (yrs) 20.3 ± 11.0
Age at HIV diagnosis (yrs) 33.6 ± 9.6
HIV diagnosed in or after 1996 11 (41%)
White 8 (30%)
Alcohol 6 (22%)
Diabetes Mellitus 1 (4%)
Weight 70.7 ± 10.0
Weight ≥ 75 Kg 11 (41%)
Cholestrol 4.5 ± 1.3
Triglycerides (TG) 2.1 ± 1.8
Cholestrol/TG ratio 5.0 ± 2.2
Platelet count (/mm3) 163 ± 65.5
Therapy received
None 5 (18%)
NRTI 4 (15%)
Duration 11.2 ± 8.4
Only HAART 11 (41%)
Duration 29.5 ± 26.5
Sequential 7 (26%)
Duration 105 ± 23.3
Steatosis 18 (67%)
Steatosis grade 1.0 ± 0.9
Necroinflammatory grade 4.4 ± 1.9
CD4 count (/mm3) 370 (130–110
HIV VL (copies/ml) UD (UD-210
UD: undetectable
Box plot showing fibrosis progression rates/year in those with (yes) and without (no) hepatic steatosisFigure 3
Box plot showing fibrosis progression rates/year in those 
with (yes) and without (no) hepatic steatosis.
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with HAART remain speculative, but could be related to
immune restoration induced changes in pro inflamma-
tory and profibrogenic cytokines, a direct effect of HAART
on liver fibrosis [21,25,26], or as indicated in this study,
the relatively lower prevalence of steatosis (Fig 4).
We however accept the limitations of this study, including
its retrospective design, and the small sample size of the
coinfected cohort. In addition liver biopsies were per-
formed in only carefully selected patients. Though this
clearly resulted in a selection bias, such a bias is true for
most studies in this area, and in our opinion is unavoida-
ble.
In conclusion despite a low prevalence of obesity and DM,
58% of HIV-HCV coinfected patients have evidence of
hepatic steatosis histologically. Absence of HAART only
therapy was independently associated with steatosis in
this study. The presence of hepatic steatosis was also asso-
ciated with more advanced hepatic fibrosis in the coin-
fected cohort. The comparatively lower prevalence of
hepatic steatosis seen in those that receive HAART only
 ≥ 3 Fibrosis stage < 3
n = 33
p value
38.3 ± 7.8 ns
24.4 ± 7.2 ns
33.1 ± 6.7 ns
23 (70%) 0.023
15 (45%) ns
12 (36%) ns
2 (6%) ns
73.5 ± 10.2 ns
13 (39%)
4.0 ± 1.0 ns
1.8 ± 1.5 ns
3.8 ± 1.3 0.02
228 ± 66.8 0.001
12 (36%) Ns
6 (18%) Ns
29.3 ± 17.1 0.16
11 (33%) Ns
30.4 ± 27.9 Ns
4 (12%) Ns
77.5 ± 47.3 0.39
17 (51%) Ns
0.5 ± 0.5 0.028
3.1 ± 1.3 0.007
0) 510 (100–1200) 0.06
955) 28.5 (UD-59540) NsPage 6 of 8
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tribute to the attenuated hepatic fibrosis that has been
observed with this therapy [17,22].
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